Veterinarian Partners — Precision Tools and Solutions for Canine Oncology
From precise diagnosis and treatment guidance to decision support
PETcura is a partner to veterinarians — not a "supplier" and certainly not a "competitor". We bring mature human-medicine precision tools to veterinary practice: organoid drug sensitivity testing delivers real efficacy data, gene sequencing for targeted drug prediction provides molecular-level evidence, and personalized mRNA immunotherapy opens a frontier path for cases with limited standard options — alongside joint research that advances both academics and clinical practice. From precise diagnosis to treatment guidance, we help doctors use the tools well and make decisions on solid evidence.
What we bring to your practice
Drug sensitivity: real efficacy data
3D organoid "avatars" test 48 drugs; a "drug map" in ~10 days — drug selection moves from trial-and-error to data-backed, saving the time window that matters
Gene sequencing: molecular evidence
A 154-gene panel with A–D evidence tiers, paraffin blocks accepted — a new decision dimension for recurrent and refractory cases
mRNA frontier: one more path
The canine personalized mRNA immunotherapy IIT — a frontier individual immune path for cases where standard care is limited or has failed
Joint research: growing together
Case data, academic publications, and clinical experience exchange — advancing with doctors and hospitals on both fronts
From precise diagnosis to treatment guidance
We help you turn "seeing deeper" into "advising better":
- Precise diagnosis: after pathology confirms "what cancer it is", sensitivity testing measures "which drugs actually work" and sequencing reveals "which targeted drug directions exist" — different layers of the same tumor, a more complete diagnostic chain
- Treatment guidance: reports are interpreted with A–D evidence tiers, stating clearly "how strong the evidence is" — the veterinarian integrates pathology, staging, and clinical judgment, so drug decisions stand on evidence
- Decision support: we provide tools and data; clinical decisions always stay with the veterinarian — all results are for licensed veterinarians to judge with the complete case
In one sentence: PETcura does not practice medicine — we make your clinical decisions more evidence-based and more confident.
Quick links
- Organoid drug sensitivity testing (48 drugs, dogs & cats) → Drug sensitivity service
- Gene sequencing for targeted drug prediction (154-gene panel, blocks accepted, coming soon) → Sequencing service
- Personalized canine mRNA immunotherapy IIT (study details & eligibility) → Study details
- Contact us → Contact
The mRNA IIT: a study we run with veterinarians
The canine personalized mRNA immunotherapy is an investigator-initiated, multi-center translational study (IIT) sponsored by PETcura with research partners (including CreateModel, AAALAC-accredited in 2024), building custom mRNA immune formulations for dogs with malignant tumors. We invite licensed veterinarians to join as co-investigators:
- Research nature: an exploratory novel medical technology study — not a commercially approved veterinary product; clear enrollment gates (LNP tolerance assessment + pathology confirmation + health/blood work + informed consent)
- Human-medicine platform: the technology path comes from mature human oncology precision platforms, not a lab start-up
- Guaranteed deliverable: every case that completes RNA sequencing receives a targeted drug guidance report even if no neoantigens are found — the owner always gains something
- Co-authorship: future academic publications credit participating veterinarians as co-investigators
Cases to consider: dogs with upcoming surgery (fresh tumor + paired normal tissue obtainable); malignant solid tumors with high recurrence after standard care (mast cell tumor, melanoma, osteosarcoma, soft tissue sarcoma, etc.); owners with strong treatment motivation who can commit to ~6 months of follow-up.
Co-investigator work (three stages):
| Stage | Work |
|---|---|
| Stage 1 | Case identification, pre-surgery communication & informed consent, LNP tolerance assessment, standardized sampling & cold-chain shipping |
| Stage 2 | Report interpretation for owners (targeted drug guidance report / neoantigen analysis) |
| Stage 3 | 8-dose injections (≥1 hour observation each), follow-up records (CRF) |
Safety requirements & responsibility boundaries:
- ≥1 hour in-clinic observation after every injection; resuscitation cart required (epinephrine, antihistamines, dexamethasone)
- Severe allergic reaction (SAE): "save the dog first" — corticosteroids per emergency protocol, report to the sponsor within 24 hours
- Co-investigators are responsible only for standard veterinary procedures within their scope of practice; underlying technology quality (sequencing accuracy, neoantigen algorithms, formulation QC) rests with PETcura and its research partners
FAQ
Q: What if no neoantigens are found?
Every case that completes RNA sequencing — with or without neoantigens, whether or not entering the treatment phase — receives a targeted drug guidance report.
Q: What is the treatment flow?
Pre-surgery communication → LNP tolerance assessment → surgery sampling → freeze or direct shipping → pathology confirmation → RNA sequencing → targeted drug report + neoantigen analysis → custom formulation (~7–9 weeks) → 8 doses (D0/D7/D14/D21/D28/D42/D63/D84) → follow-up assessment.
Q: How do we start?
Contact us; we provide the full document package (informed consent, SOPs, sampling kit, screening forms, LNP tolerance test formulation) and arrange training and enrollment support.
Contact us
Let's bring precision medicine to your practice together
Add us on WeChat petcura (note "veterinarian collaboration") or email petcura@imodels.tech — tell us about your cases and your needs, and let's see how we can help.